Search

Your search keyword '"Allergan PLC -- Product development"' showing total 5 results
Start Over Descriptor "Allergan PLC -- Product development" Journal globenewswire
5 results on '"Allergan PLC -- Product development"'

1. Global Energy-based Aesthetic Devices Market valued at $5 billion in 2021, is projected to witness a lucrative growth rate of 10% in the coming 5 years

Subjects
Allergan PLC -- Product development, Business -- Research, Product development -- Statistics, Pharmaceutical industry -- Statistics -- Product development, Time to market, Banking, finance and accounting industries, Business
Abstract

BRUSSELS, BELGIUM, Nov. 16, 2022 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=6V06CDqxYmBrrb8PlGaNaDPwbFW2y6tn9sdr5kuXtf94VGEre4iBG56ncs7bkKzT1v6hS2c7O-nXHO5jHvjRiORIT2wCV6T_NX3buD2tKMF-Fwb4QCXjdh-tIuR3p-zMhGiQT2HWl9jQ2yExmW8vxig5uYHcWa5vB1gqex7JL58= are used for a variety of skin procedures, including body sculpting, skin tightening, and resurfacing. These devices are precise, targeted medical [...]

Published
2022

2. Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight

Subjects
Allergan PLC -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Trospium -- Product development, Clinical trials -- Reports, Darifenacin -- Product development, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business
Abstract

Los Angeles, USA, Jun 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- Overactive Bladder Pipeline Shows Rapid Advancements in the Clinical Trials: A Review by DelveInsight Overactive Bladder therapies with different [...]

Published
2021

3. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Genomics, Banking, finance and accounting industries, Business, Oregon Health & Science University
Abstract

DUBLIN, Ireland and CAMBRIDGE, Mar 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to [...]

Published
2020

4. Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan Inc. -- Product development, Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genomics, Genetic research, Genes, Genetic disorders, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland and CAMBRIDGE, Jul 25, 2019 (GLOBE NEWSWIRE via COMTEX) -- Expect first patient dosing in second half of 2019 Allergan plc (NYSE: AGN), a leading global pharmaceutical company, [...]

Published
2019

5. Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Subjects
Allergan Inc. (Irvine, California) -- Product development, Allergan PLC -- Product development, Genomics, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business
Abstract

DUBLIN, Ireland and CAMBRIDGE, Mass., Aug 06, 2018 (GLOBE NEWSWIRE via COMTEX) -- Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results